

Additional supplemental

material is published online

only. To view, please visit the

journal online (http://dx.doi.

¹Faculty of Medicine, European

³Interventional Neuroradiology,

Centre Hospitalier Universitaire

de Limoges, Limoges, France

⁴Neurocirurgia Endovascular, Hospital Santa Teresa,

Correspondence to

Professor Christina Iosif,

Nicosia 87000, Cyprus; christina.iosif@gmail.com

Received 5 August 2021

Published Online First 12 January 2022

Accepted 28 November 2021

European University Cyprus,

Petropolis, Rio de Janeiro, Brazil

org/10.1136/neurintsurg-

University Cyprus, Egnomi,

²BioEMXLim, University of

Limoges Medical Faculty,

2021-018097).

Limoges, France

Cyprus

Selective arterial temporary flow arrest with balloons during transvenous embolization for the treatment of brain arteriovenous malformations: a feasibility study with MRI-monitored adverse events

Christina Iosif (1,2,3) Jose Alberto Almeida Filho (1,3,4) Clara Esther Gilbert, ³ Ali Nazemi Rafie, ³ Suzana Saleme, ³ Aymeric Rouchaud (1,2,3) Charbel Mounayer^{2,3}

ABSTRACT

Case series

Background The technique of endovascular transvenous embolization for brain arteriovenous malformations (AVMs) has emerged in the last 8 years as a very promising therapeutic alternative for otherwise incurable cases. Selective temporary flow arrest during transvenous endovascular embolization (TFATVE) is a novel adaptation of our previously described transvenous approach, which employs hyper-compliant balloons intra-arterially for the selective occlusion of arterial feeders during ethylene vinyl copolymer (EVOH) injection, in order to reduce intra-nidal pressure and increase nidi occlusion rates.

Methods We performed a feasibility study of the TFATVE technique between January 2016 and April 2020. Consecutive patients were included. All patients had at least one axial brain MRI or CT in the first 48 hours following intervention, and at least one brain MRI scan within the first postoperative month, in order to detect both silent and clinically evident adverse events. Patients' demographics, angio-architectural characteristics, total injection and procedure times, angiographic and clinical outcomes were analyzed. **Results** 22 patients underwent TFATVE during transvenous endovascular treatment of brain AVMs. Among them, 86.4% were high Spetzler-Martin's grade. Good clinical outcome (modified Rankin Scale <2) was achieved in 95.5% of the cases, with 0% of procedurerelated mortality and 4.5% of clinically significant, procedure-related morbidity. Total occlusion of the nidus was achieved in >90% of the cases at the end of the procedure and angiographic stability was achieved in all cases; 100% of the cases had angiographic cure at follow-up.

Conclusions TFATVE seems a safe and effective technique when conducted in carefully selected patients in highly specialized centers.

Check for updates

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Iosif C, Almeida Filho JA, Gilbert CE, *et al*. *J NeuroIntervent Surg* 2022;**14**:1234–1238.



The treatment of brain arteriovenous malformations (AVM) represents a therapeutic challenge, regardless of the chosen modality. Nevertheless, for ruptured lesions, there is a clear clinical benefit^{1–3} of invasive treatments. With a reported yearly risk of $6-18\%^{2-4}$ and up to 34.4% per annum for ruptured lesions with exclusively deep venous drainage,⁵ AVM rupture is retained as the most important factor of disability and mortality.³

Although necessary, invasive treatment for AVMs with deep or eloquent localizations remains problematic in many cases, with high complication rates and moderate technical outcomes for neurosurgical techniques.^{5–11} The endovascular transvenous approach has emerged as a very promising therapeutic alternative for technically challenging and/or otherwise incurable brain AVMs.¹² The technique is particularly beneficial in order to cure small, deep niduses or residual niduses, as a final stage of treatment.^{12–14}

The selective temporary flow arrest during transvenous endovascular embolization (TFATVE) is an adaptation our previously described transvenous embolization technique.¹² This novel adaptation employs hyper-compliant balloons intra-arterially, for the selective reduction of intra-nidal pressure, allowing for the treatment of larger nidi. We aim to describe the technique and assess its safety.

METHOD

Study design and participants

This is a cohort study on consecutive patients treated with the TFATVE technique between January 1, 2016 and April 30, 2020. The institutional review board and ethics committee approved the study protocol. All subjects or legal guardians signed an informed consent form. This study was performed in accordance with the Code of Medical Ethics of the World Medical Association (Declaration of Helsinki, 2014) and reported according to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines.¹⁵

Patient selection and endovascular technique

Among 335 patients with brain AVMs, who underwent endovascular treatment at our institution during the same period, 22 patients underwent treatment with the TFATVE technique.

The patients were selected for this technique according to our previously reported criteria for transvenous endovascular embolization, such as small and residual nidi, otherwise inaccessible by endovascular or surgical means and deep location.¹² The endovascular transvenous embolization has been extensively described by our group in previous

losif C, et al. J NeuroIntervent Surg 2022;14:1234–1238. doi:10.1136/neurintsurg-2021-018097



Š

copyright.

for

uses related

đ

text

and

mining

` >

I training, and similar

technolog

les

New devices and techniques

reports.^{12 14 16} The TFATVE technique was privileged over our standard transvenous endovascular approach, on the basis of larger draining veins and slightly larger nidi (but <6 cm), privileging deep locations and deep venous drainage, as we systematically do for our standard transvenous embolization technique. We defined a venous collector suitable for TFATVE as a main collector at least twice the diameter of the corresponding contralateral vein.

All procedures were performed in a biplane flat panel angiography suite (Artis Zee biplane, Siemens Healthineers), under general anesthesia. Intravenous 3000 IU heparin was administered before selective intracranial navigation. The core technique of the transvenous embolization for AVMs has been described elsewhere.12

The balloon catheter (Eclipse, Eclipse 2L, Scepter XC, Scepter C or Hyperform) was positioned in a straight segment of the middle cerebral artery (usually M2), anterior cerebral artery (usually A2), or posterior cerebral artery (usually P2), according to the AVM anatomy and feeders. The choice of feeders for the temporary flow arrest were selected on the basis of the larger and hemodynamically dominant feeders for the nidus supply. The goal of the balloon position was to occlude the ostium of the feeder, without it being necessarily positioned inside the feeder, since the ethylene vinyl copolymer (EVOH) injections were always performed by the transvenous route, with one or dual injection; no arterial EVOH injection was performed in this cohort, thus it was not necessary to increase the risk of further, hyperselective navigation of the balloons inside the arterial feeders.

A flexible, dimethyl sulfoxide (DMSO)-compatible microcatheter was then navigated coaxially to selectively catheterize the AVM's draining vein, as close as possible to the nidus. In order to allow a continuous injection and a faster penetration of EVOH in the nidus and minimize backflow in the vein, coils were used in the venous side for veins $\geq 5 \text{ mm}$ in diameter, with low packing density, without use of glue; in cases with a vein <5 mmwe tolerated a reflux of EVOH in the order of 3 cm. The arterial balloon was inflated before each transvenous injection; every 5 min the balloon was deflated, and we waited 2 min for reperfusion after inflating the balloon again. During the interventions we maintained a systematic mean arterial pressure 20mm Hg lower than the usual for each patient, using appropriate doses of intravenous urapidil, with an electrical syringe. No further anticoagulant therapy was administered post-intervention.

Follow-up imaging

The patients underwent brain MRI performed in a 3T system (Achieva, Philips Medical System) or, in cases of contraindication, a CT scan, at 24-28 hours post-TFATVE. A second brain MRI was performed within a month following TFATVE. Four-axis selective digital subtraction angiography (DSA) was performed at 6 months post-intervention, and, if complete occlusion was confirmed, MRI was performed at the 24 month follow-up. MRIs were evaluated by senior neuroradiologists and included systematically diffusion-weighted imaging (DWI) sequences with the creation of apparent diffusion coefficient (ADC) maps; gadolinium injections were performed, whenever deemed necessary.

Clinical follow-up

All patients had a neurological examination by a senior neuroradiologist and anesthesiologist before treatment, at awakening, at discharge, and at 6 month follow-up.

Statistical analysis

Descriptive statistical analysis was performed, using the Student t-test for quantitative data, after appropriate testing for normal distribution (de Agostino-Pearson test) and the χ^2 test for qualitative data. The Statistica software (StatSoft, GE) was used. The level of statistical significance was $p \le 0.05$.

RESULTS

Patient population

Twenty-two patients-14 (63.6%) men and eight (36.4%) women, mean age 39 years (SD 16, 95% CI for the mean: 33 to 47), among them two adolescents—were treated for a brain AVM with the technique of selective TFATVE. Their initial modified Ranking Score (mRS) at admission was 0 for 13 (59.0%) patients, 1 for four (18.1%) patients, 2 for three (13.6%) patients, 4 for one (4.5%) patient, and 5 for one (4.5%) patient. Clinical presentation included intraventricular hemorrhage in seven (31.8%) patients, intracranial hematoma in six (27.3%), subarachnoid hemorrhage in one (4.5%), epilepsy in three (13.6%), stroke in one (4.5%), headache in two (9.1%)patients, and 'other' in two (9.1%) of the cases. Spetzler-Martin patients, and other in two (9.1%) of the cases. Spetzler-Martin (S-M) classification was 1 for one (4.5%) case, 2 for 6/22 (27.3%), 3 for 13/22 (59.1%), 4 for one (4.5%) case, and 5 for **G** one (4.5%) case. Nineteen out of 22 cases (86.4%) were high S-M grade (online supplemental table)

AVM characteristics

The AVMs were ruptured in 14/22 (63.6%) and unruptured in 8/22 (36.4%) of the cases. Nidi locations included eloquent areas in most of the cases (17/22 cases, 77.3%). Nidi sizes were <3 cm in 12 (54.5%) cases, 3-6 cm in nine (40.9%) case, and >6 cm in one (4.5%) case. Associated aneurysms were identified in 6/22 cases (27.3%), among which were two cases of aneurysms located at the level of Willis (9.1%) and 4/22 cases with intranidal aneurysms (18.2%). A venous pouch was present in one (4.5%) case.

The AVMs were located in the hemispheres in 14/22 (63.6) cases, the basal ganglia in three cases (13.6%), the corpus callosum in one case (4.5%), the choroid plexus in another case, and the posterior fossa in three cases (13.6%). The AVMs had exclusively deep venous drainage in 9/22 (40.9%) cases, and included, but were not limited to, deep venous drainage in 5/22 (22.7%) cases, while the remaining 8/22 (36.4%) cases had exclusively superficial venous drainage.

Technical facts

The temporary flow arrest was performed in arterial feeders of the anterior circulation in 13/22 (59.1%) cases, among which were three cases (3/22, 13.6%) with two balloons in two arterial feeders, and in the posterior circulation in 5/22 (22.7%) cases, among which was one case (1/22, 4.5%) with two balloons in two feeders. There were 4/22 (22.7 %) cases with temporary balloon occlusion in both the anterior and posterior circulations (figure 1). In cases with two balloons, these were inflated during the EVOH injections simultaneously. The EVOH injection was always transvenous and did not always correspond to dual transvenous injection.

The patients had overall one session until cure in nine (40.9%) cases, two sessions in eight (36.4%) cases, three sessions in two (9.1%) cases, and more than three sessions in three cases (13.6%). In the vast majority of the cases (20/22, 90.9%) the session with the selective, temporary flow arrest was the last session; only in two cases (9%) was the flow arrest session followed by another,



Figure 1 Patient with a history of intraventricular bleeding referred for arteriovenous malformation (AVM) treatment. Digital subtraction angiography: (A) frontal and (B) lateral view, showing a left hypothalamic AVM, with a nidus of maximal diameter of 2.5 cm, with venous drainage through the basal veins of Rosenthal, bilaterally (arrows); (C) single shot during the procedure showing two eclipse S 6×12 mm (Balt Extrusion, Montmorency, France) balloons, one in the left internal carotid artery (black arrow) and the other in the left posterior cerebral artery (arrowhead) and a Marathon microcatheter (Medtronic, CA) in the posterior thalamic vein (white arrow); (D) and (E), DSA on frontal and lateral view, respectively, showing complete obliteration of the nidus at the end of the procedure; (F), single shot showing the cast of EVOH (Squid 18) at the control and the end of the procedure; (G) and (H), DSA on frontal and lateral view, respectively, showing complete obliteration of the nidus at 6 months control; (I) axial MRI at 6 months showing no ischemic complications; absence of periprocedural or postprocedural complications during hospitalization and follow-up. DSA, digital subtraction angiography; EVOH, ethylene vinyl copolymer.

last session (by simple transvenous embolization), in order to obtain total occlusion of the nidus. The transvenous approach involved the use of loose coiling in the draining vein in 15/22(68.2%) of the cases; for the rest of the cases (7/22, 31.8%) the transvenous injection was performed without the adjunct use of coils. One case (4.5%) was performed with dual microcatheter injection in the venous side.

The mean total injection time of the liquid embolic material by the transvenous route was 10 ± 6 min (arithmetic mean \pm SD) and was delivered as a single injection in 9/22 (40.9%) cases, as two injections in 8/22 (36.4%), as three injections in 3/22 (13.6%), and as more than three injections in 2/22 (9%) cases. The time length per injection ranged from 3 to 8 min. The mean amount of liquid embolic material used per procedure was $13.5 \pm 20 \text{ mL}$ (arithmetic mean ± SD, median 9 mL). Mean total procedure time was 88 min (±SD: 44 min, 95% CI of the mean: 68 to 106 min), defined as groin puncture to closure.

Clinical outcomes

mRS scores at discharge were 0 for 11/22 (50.0%) patients, 1 for 3/22 (13.6%), 2 for 4/22 (18.2%), 3 for 3/22 (13.6%), and 4 for 1/22 (4.5%) patients. At 6 month controls, mRS was 0 for 11/22

 Table 1
 Clinical evolution of patients by means of modified Ranking Scale score

Pre-Tx		Disc	:harg	je mF	lS (n=	=22)	6 m (n=	onth 22)	mRS	5	≥12 (n=2	mor 22)	nth m	nRS
mRS	No. of patients	0	1	2	3	4	0	1	2	3	0	1	2	3
0	12	11			1		10	1		1	10			
1	4		3	1			1	3			2	2		
2	3			3					3		1		2	
3	0				0									
4	3				2	1		2		1		2	1	
Totall	22	11	3	4	3	1	11	6	3	2	13	5	3	1

Gray-shaded numbers indicate the number of patients with clinical worsening in regard to pretreatment clinical status. Light gray indicates worsening non-related to the procedure or the AVM of the patient.

Pink shaded numbers indicate the number of patients with clinical improvement in regard to pretreatment clinical status.

AVM, arteriovenous malformation; mRS, modified Rankin Scale; Tx, treatment.

Protected by copyright, including for (50.0%) patients, 1 for 6/22 (27.3%), 2 for 3/22 (13.6%), and 3 for 2/22 (9.1%) patients. Respective values at 1 year were 13/22 (59.1%), 5/22 (22.7%), 3/22 (13.6%), and 1/22 (4.5%). At 6 and 12 months 91% and 95.5% of the patients were independent in their everyday lives, respectively (table 1).

Angiographic outcomes

In all but two cases, in 20/22 (90.9%) cases at the end of the procedure there was complete occlusion of the AVM. The latest DSA follow-up was 12 months and it showed stability of the angiographic outcome for all patients. The small nidus remnant of one patient was subsequently addressed by transvenous embolization (online supplemental table).

Clinical and angiographic evolution

The overall rate of adverse events was 9% and the percentage of good clinical outcome (mRS <2) was 95.5% at 1 year postintervention. Procedure-related and overall mortality was 0%. Overall procedure related morbidity was 9% and clinically significant procedure-related morbidity was 4.5%. Absence of delayed re-bleeding was found. Total occlusion of the nidus and angiographic stability of the result was achieved in all cases.

Axial imaging follow-up of adverse events

Eighteen patients (18/22 (82%)) had a brain MRI within 48 hours post-intervention; the remaining 4/22 were initially monitored by CT scan. All of the patients had at least one postprocedure brain MRI, either during hospitalization, or during follow-up within the first month after discharge. Absence of imaging-confirmed venous ischemia was documented for all patients, including absence of extensive vasogenic edema of the region in which the nidus was located, absence of hemorrhage of the region, and absence of thrombus inside a vein. Vasogenic edema around the cast of EVOH, without a decrease in ADC values, was found in 8/18 (44%) of the cases and had resolved on follow-up imaging.

There was one case with early-onset, clinically evident arterial ischemia (1/22, 4.5%) (infarct with low ADC values and arterial distribution), which is described below. There was one case (1/22)(4.5%)) with two clinically silent spots on the post-procedure MRI. There was no late-onset hemorrhage, or late-onset arterial or venous ischemia, detected in the axial imaging.

uses related

đ

text

and

٩

training, and

l simi

lar

technolog

lles

Protected

by co

pyright

includi

Bui

for uses

related

to text

tand

data

mining

. ۲

l, and

<u>0</u>

out

Complications

All cases were technically feasible. Absence of cerebral venous ischemia, early or delayed, was confirmed by axial imaging for all treated patients. There was one case of arterial ischemia (1/22 (4.5%)), in a patient who was treated for a right temporal AVM, S-M 3. The AVM's feeders were the right anterior choroidal artery and right anteromedial branches of the posterior cerebral artery, and the venous drainage was by a single, exclusively deep collector to the basal vein of Rosenthal. The transvenous injection was performed with TFATVE with two balloons, inflated in the right middle cerebral artery (M1 segment) and in the right posterior cerebral artery, respectively. The total EVOH injection time was 7 min 55 s and the total procedure time 48 min (groin puncture to closure).

In the immediate post-procedure period, the patient experienced left arm and leg hemiplegia and hemianesthesia and left homonymous hemianopia. The MRI showed restricted diffusion in the posterior limb of the internal capsule and perilesional vasogenic edema around the nidus. The perforators were patent and visible on the control angiogram at the end of the procedure. The symptoms partially regressed during hospitalization and further improved during follow-up. The patient, who had an mRS score of 1 before the treatment, was discharged with mRS 2 and was mRS 1 at 6 months and mRS 0 at 1 year.

In another case (1/22 (4.5%)), a small hematoma was detected in the first hours post-treatment, in a patient with a ruptured AVM, undergoing the second and last embolization session for a S-M 3, right temporal AVM. The embolization included two EVOH injections, one of 6 min 4s and the other of 5 min 48s. Total procedure time (groin puncture to closure) was 200 min. The patient suffered deficit of the right side, which partially regressed during hospitalization. The patient was mRS 3 and 2 at 6- and 12-month follow-up evaluations, respectively.

DISCUSSION

Deep AVMs and, until recently, inaccessible angioarchitectural types or post-treatment nidi remnants have been lately addressed by transvenous embolization, with impressively high cure rates.^{12 16} Within the last 5 years an increasing number of studies show that the transvenous route may be curative in otherwise inaccessible cases.^{16 17} The relative indications include cases with a single draining vein, deep venous drainage, and relatively small nidi and/or last embolization sessions or residual nidi.

In this article we describe a novel adaptation of our previously described endovascular transvenous technique,¹² aiming to further increase the retrograde penetration of the liquid embolic agent and to increase safety during the injection, for slightly larger nidi and larger venous collectors. To the best of our knowledge, this is the first clinical series of brain AVM treatment, with the aid of selective hypotension using hypercompliant arterial balloons, without transarterial EVOH injection from the transiently occluded pedicle and without pharmacological flow arrest. The balloons were used to reduce the AVM inflow, creating a local flow arrest during the transvenous injection of liquid embolic agent, thus selectively decreasing the intranidal inflow, in order to obtain a microenvironment favorable to the retrograde, transvenous progression of the liquid agent into the nidus. Massoud et al had already described the benefits of local hypotension in swine models,^{18 19} providing evidence of such a microenvironment for the endovascular treatments of AVMs. In accordance with their findings, Nornes and Grip reported that clipping of the main feeder of an AVM results in loss of the draining vein pressure from 18 mm Hg to 10 mm Hg.²⁰ Our

clinical and angiographic results are in agreement with these experimental findings.

Even though invasive treatments of highly-eloquent lesions are associated with poor clinical outcome,²¹ the series presented herein, in accordance with our previous series on transvenous embolization, showed that 91% of the patients were mRS 0-2 at 6 months, even though 64% had a hemorrhagic presentation. This series had equally important total occlusion rates, as our earlier works on transvenous embolization for challenging brain AVMs and higher compared with other series, even compared with series with lower S-M grades. Radiological cure and angiographic stability at 1 year was achieved in 95% (21/22) and 100% (22/22) of the series, respectively. We attribute this high percentage to the better progression of the embolic agent in retrograde fashion, under circumstances of selective flow arrest, thus impeding antegrade flow forces and thus lowering pressure in the concerned pedicles during injection.

We were able to inject a mean of 14 mL of liquid embolic material per embolization, which allowed us to occlude nidi, in many cases much larger than usually indicated for transvenous approaches (3-6 cm in 9/22 (40.9%) cases), usually in one or two injections (17/22 (77.3%)), all during one session. To the best of our knowledge this is the first report of such a high performance in terms of effectiveness in endovascularly occluding larger nidi, in high S-M cases. The mean total injection time of the liquid embolic material by the transvenous route remained relatively low $(10 \pm 6 \min)$.

The mean time length per transvenous EVOH injection varied from 3 to 8 min, which corresponded to a time frame mostly within the 5 min window of inflation of the balloon for flow arrest. We found that the temporary flow arrest allowed for more rapid progression of the EVOH injected within this 5 min window, allowing for better and more rapid progression of the embolic material with the nidus. The small window did not affect the injections negatively. In some cases after deflation of the balloon we would maintain a positive pressure for $1-2 \min$ further, in order for the EVOH to continue to progress. We did not experience any negative effects from the balloon being deflated.

The reverse (transvenous) pressure cooker technique was training described recently by the team of Chapot and employs a transvenous plug of coils and cyanoacrylate glue, followed by transvenous embolization.²² In the technique described herein, loose coiling on the venous site may be implicated in larger venous outlets, but without occlusion of the venous site before occlusion of the nidus, just as an adjunctive measure to reduce outflow in some cases. The key factor in the technique presented herein is use of a selective balloon occlusion, which allows for pressure and flow reduction/arrest without temporarily occluding the vein before the nidus. We only experienced one case (4.5%) of a small hematoma detected in the first hours post-treatment in a patient with a ruptured AVM.

Since selective balloon inflation remains an additional invasive element during the procedure, we sought to assess the additional risk objectively and to correlate it with the benefit of this novel approach. For this reason we were the first team to monitor all cases and adverse events, even silent ones, by MRI. Our findings confirmed absence of neither early nor delayed venous ischemia. Silent arterial ischemic spots were found in one case (4.5%) and clinically evident arterial ischemic in another (4.5%).

Even though the concept of selective flow arrest is novel, systemic cardiac arrest and hypotension have been already attempted, aiming at better control of the liquid embolic agent

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

New devices and techniques

and better results. Nevertheless, the risks of complications from these techniques are not negligible.^{23 24} Multiple periods of cardiac arrest and hypotension have the potential to produce cardiac and neurologic injury.²⁵ Bendok *et al* and Lee *et al* described cardiac complications from adenosine use, such as increased troponin, ventricular tachyarrhythmias, atrial fibrillation and bradyarrhythmias.^{26 27} Al-Mousa *et al* point out that there are several case reports of bronchospasm after adenosine administration.²⁵

In a recent publication by Waqas *et al*, flow control was attempted in 12 cases, using concurrent transient rapid ventricular pacing or intravenous adenosine and temporary occlusion of arterial feeders by balloon inflation, while employing retrograde, obstructive coiling and N-butyl cyanoacrylate (NBCA) injection of the vein, with subsequent EVOH injection transvenously in retrograde fashion. In this study the authors attempted to exploit a complete flow arrest-total flow control, by simultaneous pharmacological and mechanical means, transiently occluding the arterial pedicles and permanently occluding the draining vein. They reported 20% of intraprocedural hemorrhagic complications.²⁸

While in our series there are similar inclusion criteria, our technique is less aggressive, without systemic pharmacological cardiac arrest, neither total inflow nor outflow flow arrest. The loose coiling used in some cases in the vein was destined to reduce the rapid outflow, and did not have a goal of occluding the veins. We relied solely on a selective flow arrest, which to our experience was enough for the occlusion of the selected nidi, with fewer intraprocedural complications.

As opposed to other techniques employing transvenous embolizations, we neither aimed for complete venous occlusion in the initial stages of the treatment, nor for transarterial injections through the balloon. We aimed to selectively reduce the inflow and pressure in the nidi, with the least invasive way possible, giving a further boost to our standard transvenous embolization technique, without additional risk coming from more aggressive approaches.

With hemorrhagic clinical presentation in 63.6% of our cases and high S-M scores in 86.4% of them, we believe that with 0% mortality and 4.5% clinically significant complications in our series the technique seems promising, given the reported complication rates in the range of 20% for these types of lesions.²⁹ Good clinical outcome (mRS <2) was found in 95.5% of the patients in our series, 6 months after intervention, with an initial total occlusion rate of over 90% and a total occlusion rate of 100% at follow-up.

LIMITATIONS

Since this is a small series of a new endovascular technique, the sample is limited and the statistical analysis results have limited value. Nevertheless, they may depict directions for further analysis and attention with larger databases in the future.

CONCLUSION

The selective temporary flow arrest during transvenous embolization seems a safe and effective technique, especially for high-grade AVMs which have been previously treated. It should be employed in carefully selected patients and in highly specialized centers. Further research with larger series and case-controlled studies are required to validate these findings.

Contributors Conception and design of study: CI and CM. Acquisition of data: JAAF, CEG and ANR. Analysis and/or interpretation of data: CI, CM, AR, SS. Drafting the manuscript: CI, JAAF. Revising the manuscript critically for important intellectual

content: CI, CM. Approval of the version of the manuscript to be published: CI, CM, AR, SS, JAAF, ANR and CEG.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Consent obtained directly from patient(s)

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Christina losif http://orcid.org/0000-0003-1001-2331 Jose Alberto Almeida Filho http://orcid.org/0000-0002-5622-0702 Aymeric Rouchaud http://orcid.org/0000-0003-0902-3375

REFERENCES

- Wilkins RH. Natural history of intracranial vascular malformations: a review. *Neurosurgery* 1985;16:421–30.
- 2 da Costa L, Wallace MC, ter Brugge KG, et al. The natural history and predictive features of hemorrhage from brain arteriovenous malformations. *Stroke* 2009:40:100–5.
- 3 Hernesniemi JA, Dashti R, Juvela S, *et al*. Natural history of brain arteriovenous malformations: a long-term follow-up study of risk of hemorrhage in 238 patients. *Neurosurgery* 2008;63:823–9.
- 4 Crawford PM, West CR, Chadwick DW, et al. Arteriovenous malformations of the brain: natural history in unoperated patients. J Neurol Neurosurg Psychiatry 1986;49:1–10.
- 5 Stapf C, Mast H, Sciacca RR, *et al*. Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. *Neurology* 2006;66:1350–5.
- 6 Hernesniemi J, Romani R, Lehecka M, et al. Present state of microneurosurgery of cerebral arteriovenous malformations. Acta Neurochir Suppl 2010;107:71–6.
- 7 Potts MB, Young WL, Lawton MT, et al. Deep arteriovenous malformations in the basal ganglia, thalamus, and insula: microsurgical management, techniques, and results. *Neurosurgery* 2013;73:417–29.
- 8 Ferch RD, Morgan MK. High-grade arteriovenous malformations and their management. J Clin Neurosci 2002;9:37–40.
- 9 Lawton MT, Hamilton MG, Spetzler RF. Multimodality treatment of deep arteriovenous malformations: thalamus, basal ganglia, and brain stem. *Neurosurgery* 1995;37:29–36.
- Hamilton MG, Spetzler RF. The prospective application of a grading system for arteriovenous malformations. *Neurosurgery* 1994;34:2–6.
- 11 Fleetwood IG, Marcellus ML, Levy RP, et al. Deep arteriovenous malformations of the basal ganglia and thalamus: natural history. J Neurosurg 2003;98:747–50.
- 12 Iosif C, Mendes GAC, Saleme S, et al. Endovascular transvenous cure for ruptured brain arteriovenous malformations in complex cases with high Spetzler-Martin grades. J Neurosurg 2015;122:1229–38.
- 13 Mendes GAC, losif C, Silveira EP, et al. Transvenous embolization in pediatric plexiform arteriovenous malformations. *Neurosurgery* 2016;78:458–65.
- 14 Mendes GAC, Silveira EP, Caire F, et al. Endovascular management of deep arteriovenous malformations: single institution experience in 22 consecutive patients. *Neurosurgery* 2016;78:34–41.
- 15 von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453–7.
- 16 Mendes GAC, Kalani MYS, Iosif C, *et al*. Transvenous curative embolization of cerebral arteriovenous malformations: a prospective cohort study. *Neurosurgery* 2018;83:957–64.
- 17 Fang Y-B, Byun J-S, Liu J-M, et al. Transvenous embolization of brain arteriovenous malformations: a systematic review and meta-analysis. J Neurosurg Sci 2019;63:468–72.

New devices and techniques

- 18 Massoud TF, Hademenos GJ. Transvenous retrograde nidus sclerotherapy under controlled hypotension (TRENSH): a newly proposed treatment for brain arteriovenous malformations--concepts and rationale. *Neurosurgery* 1999;45:351–66.
- 19 Massoud TF, Hademenos GJ, Young WL, et al. Can induction of systemic hypotension help prevent nidus rupture complicating arteriovenous malformation embolization?: analysis of underlying mechanism achieved using a theoretical model. AJNR Am J Neuroradiol 2000;21:1255–67.
- Nornes H, Grip A. Hemodynamic aspects of cerebral arteriovenous malformations. J Neurosurg 1980;53:456–64.
- 21 Schaller C, Schramm J, Haun D. Significance of factors contributing to surgical complications and to late outcome after elective surgery of cerebral arteriovenous malformations. J Neurol Neurosurg Psychiatry 1998;65:547–54.
- 22 Koyanagi M, Mosimann PJ, Nordmeyer H, et al. The transvenous retrograde pressure cooker technique for the curative embolization of high-grade brain arteriovenous malformations. J Neurointerv Surg 2021;13:637–41.
- 23 Hashimoto T, Young WL, Aagaard BD, et al. Adenosine-Induced ventricular asystole to induce transient profound systemic hypotension in patients undergoing endovascular therapy. Anesthesiology 2000;93:998–1001.

- 24 Pile-Spellman J, Young WL, Joshi S, *et al*. Adenosine-induced cardiac pause for endovascular embolization of cerebral arteriovenous malformations: technical case report. *Neurosurgery* 1999;44:881–6.
- 25 AL-Mousa A, Bose G, Hunt K, et al. Adenosine-assisted neurovascular surgery: initial case series and review of literature. *Neurosurg Rev* 2019;42:15–22.
- 26 Bendok BR, Gupta DK, Rahme RJ, et al. Adenosine for temporary flow arrest during intracranial aneurysm surgery: a single-center retrospective review. *Neurosurgery* 2011;69:815–21.
- 27 Lee SH, Kwun BD, Kim JU, *et al*. Adenosine-Induced transient asystole during intracranial aneurysm surgery: indications, dosing, efficacy, and risks. *Acta Neurochir* 2015;157:1879–86.
- 28 Waqas M, Dossani RH, Vakharia K, *et al.* Complete flow control using transient concurrent rapid ventricular pacing or intravenous adenosine and afferent arterial balloon occlusion during transvenous embolization of cerebral arteriovenous malformations: case series. *J Neurointerv Surg* 2021;13:324–30.
- 29 Baharvahdat H, Blanc R, Fahed R, et al. Endovascular treatment as the main approach for Spetzler-Martin grade III brain arteriovenous malformations. J Neurointerv Surg 2021;13:241–6.

Supplementary table

no	Age	Clinical presentation	Supra or Infratentorial	Nidus Size (cm)	Drainage	Spetzler Martin	no embo sessions	TVETFA session	no of balloons and circulation	Ctrl DSA 6 m	Periprocedural and posprocedural complications	No injections of EVOH	total time of EVOH injection min	total procedure time minutes
1	30s	Headache	supratentorial	1	deep	3	1	last	anterior and posterior circ	total occl.	arterial ischemia	1	8	48
2	30s	intracranial hematoma	both	1	deep	3	1	last	posterior circ one balloon	total occl.	none	1	4	45
3	60s	intracranial hematoma	infratentorial	1	superficial	3	1	last	posterior circ 2 balloons	total occl.	none	1	7	52
4	50s	SAH	supratentorial	2	superficial	3	2	one before the last	anterior circ one balloon	total occl.	none	2	14	46
5	50s	ischemic stroke	supratentorial	2	both	3	3	last	anterior circ 2 balloons	total occl.	none	2	12	202
6	60s	intracranial hematoma	supratentorial	1	superficial	2	1	last	posterior circ one balloon	total occl.	none	1	4	49
7	20s	intraventricular hemorhage	supratentorial	1	deep	3	1	last	anterior circ one balloon	total occl.	none	1	5	90
8	50s	intraventricular hemorhage	supratentorial	1	superficial	2	1	last	posterior circ one balloon	total occl.	none	1	5	67
9	30s	epilepsy	supratentorial	2	superficial	2	2	last	anterior circ one balloon	total occl.	none	2	10	72
10	10s	epilepsy	supratentorial	2	both	3	2	last	anterior circ one balloon	total occl.	none	1	6	67
11	40s	intraventricular hemorhage	supratentorial	2	deep	3	2	last	anterior and posterior circ	total occl.	none	2	9	123
12	50s	Headache	supratentorial	2	both	3	3	last	anterior circ one balloon	total occl.	none	1	5	113
13	40s	intraventricular hemorhage	supratentorial	2	deep	4	4	one before the last	anterior and posterior circ	total occl.	none	2	8	64

		intraventricular	cuprotontorial			2			anterior circ 2	total				
14	20s	hemorhage	supratentonal	2	superficial	Z	4	last	balloons	occl.	none	2	10	70
		intracranial	h a th			-			anterior and	small				
15	10s	hematoma	both	3	deep	5	6	last	posterior circ	remnant	none	5	31	159
		intraventricular	cuprotontorial			2			Anterior circ one	total				
16	40s	hemorhage	supratentonal	1	deep	3	1	last	balloon	occl.	none	3	13	90
		intracranial	infratantarial			2			posterior circ one	total				
17	40s	hematoma	iniratentorial	1	deep	3	1	last	balloon	occl.	none	2	9	130
			cuprotontorial			n			anterior circ one	total				
18	20s	epilepsy	supratentonal	2	superficial	Z	2	last	balloon	occl.	none	4	16	122
		intraventricular	cuprotontorial			2			anterior circ 2	total				
19	20s	hemorhage	supratentonal	1	both	3	2	last	balloons	occl.	none	2	9	60
	200	intracranial	supratontorial	1	doop	2	2		anterior circ one	total				
20	505	hematoma	suprateritorial	1	ueep	2	2	last	balloon	occl.	none	3	15	54
	606	incidential	cuprotontorial	1	hath	2	2		anterior circ one	total				
21	60S	incidentia	supratentonal	T	both	3	2	last	balloon	occl.	none	3	17	152
	40c	incidential	supratontorial	1	cuporficial	1	1		anterior circ one	total				
22	405	incluential	supratentonal	1	superficial	1	1	last	balloon	occl.	none	1	5	52

no	Rankin pre embolization	Rankin post embolization	Ctrl mRS at six months	Ctrl mRS 12 months
1	1	2	1	0
2	0	0	0	0
3	2	2	2	2
4	4	4	3	2
5	0	3	3	3
6	0	0	0	0
7	0	0	0	0
8	0	0	0	0
9	0	0	0	0
10	0	0	0	0
11	0	0	0	0
12	0	0	0	0
13	1	1	1	1
14	4	3	1	1
15	2	2	2	0
16	2	2	2	2
17	1	1	1	1
18	0	0	1	1
19	4	3	1	1
20	1	1	0	0
21	0	0	0	0
22	0	0	0	0
	no 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	no Rankin pre embolization 1 1 2 0 3 2 4 4 5 0 6 0 7 0 8 0 9 0 10 0 11 0 12 0 13 1 14 4 15 2 16 2 17 1 18 0 19 4 20 1 21 0 22 0	no Rankin pre embolization Rankin post embolization 1 1 2 2 0 0 3 2 2 4 4 4 5 0 3 6 0 0 7 0 0 8 0 0 9 0 0 10 0 0 11 0 0 12 0 0 13 1 1 14 4 3 15 2 2 16 2 2 17 1 1 18 0 0 19 4 3 20 1 1 21 0 0 22 0 0	no Rankin pre embolization embolization Rankin post embolization Ctrl mRS at six months embolization 1 1 2 1 2 0 0 0 3 2 2 1 4 4 3 1 5 0 3 3 6 0 0 0 7 0 0 0 8 0 0 0 9 0 0 0 10 0 0 0 11 0 0 0 0 12 0 0 0 0 13 1 1 1 14 4 3 1 15 2 2 2 1 16 2 2 2 1 18 0 0 1 1 19 4 3 1 1 2<

Date:	10/31/2021
Your Name:	Ali Nazemi Rafie
Manuscript Title:	Selective arterial temporary flow arrest with balloons during transvenous embolization for the treatment of brain arteriovenous malformations: a feasibility study with MRI-monitored adverse events
Manuscript Number (if known):	2021-018097.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Nam relat	ne all entities with whom you have this tionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	√	None Time frame: past 36 month None	Click the tab key to add additional rows.
3	Royalties or licenses	√	None	

1

		Name all entities with whom you have this	Specifications/Comments (a.g., if payments were
		relationship or indicate none (add rows as needed)	made to you or to your institution)
4	Consulting fees	√ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	√ None	
6	Payment for expert testimony	√ None	
7	Support for attending meetings and/or travel	√ None	
8	Patents planned, issued or pending	√ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	√ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√ None	

		Nam relat	e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	√	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√ 	None		
13	Other financial or non-financial interests	√	None		
Plea	Please place an "X" next to the following statement to indicate your agreement:				
	I certify that I have	answe	red every question and have not altered the wor	ding of any of the questions on this form.	

Date:	10/31/2021
Your Name:	Aymeric Rouchaud
Manuscript Title:	Selective arterial temporary flow arrest with balloons during transvenous embolization for the treatment of brain arteriovenous malformations: a feasibility study with MRI-monitored adverse events
Manuscript Number (if known):	2021-018097.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Nam relat	ne all entities with whom you have this tionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	√	None Time frame: past 36 month None	Click the tab key to add additional rows.
3	Royalties or licenses	√	None	

1

		Name all entities with whom you have this	Specifications/Comments (a.g., if payments were
		relationship or indicate none (add rows as needed)	made to you or to your institution)
4	Consulting fees	√ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	√ None	
6	Payment for expert testimony	√ None	
7	Support for attending meetings and/or travel	√ None	
8	Patents planned, issued or pending	√ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	√ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√ None	

		Nam relat	e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	√	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√ 	None		
13	Other financial or non-financial interests	√	None		
Plea	Please place an "X" next to the following statement to indicate your agreement:				
	I certify that I have	answe	red every question and have not altered the wor	ding of any of the questions on this form.	

Date:	10/31/2021
Your Name:	Clara-Esther Gilbert
Manuscript Title:	Selective arterial temporary flow arrest with balloons during transvenous embolization for the treatment of brain arteriovenous malformations: a feasibility study with MRI-monitored adverse events
Manuscript Number (if known):	2021-018097.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Nam relat	ne all entities with whom you have this tionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	√	None Time frame: past 36 month None	Click the tab key to add additional rows.
3	Royalties or licenses	√	None	

1

		Name all entities with whom you have this	Specifications/Comments (a.g., if payments were
		relationship or indicate none (add rows as needed)	made to you or to your institution)
4	Consulting fees	√ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	√ None	
6	Payment for expert testimony	√ None	
7	Support for attending meetings and/or travel	√ None	
8	Patents planned, issued or pending	√ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	√ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√ None	

		Nam relat	e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	√	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√ 	None	
13	Other financial or non-financial interests	√	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			
	I certify that I have	answe	red every question and have not altered the wor	ding of any of the questions on this form.

Date:	10/31/2021
Your Name:	Christina losif
Manuscript Title:	Selective arterial temporary flow arrest with balloons during transvenous embolization for the treatment of brain arteriovenous malformations: a feasibility study with MRI-monitored adverse events
Manuscript Number (if known):	2021-018097.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial planning of the work		
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	√ None	Click the tab key to add additional rows.	
3	Royalties or licenses	√ None		

1

		Name all entities with whom you have this	Specifications/Comments (a.g., if payments were
		relationship or indicate none (add rows as needed)	made to you or to your institution)
4	Consulting fees	√ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	√ None	
6	Payment for expert testimony	√ None	
7	Support for attending meetings and/or travel	√ None	
8	Patents planned, issued or pending	√ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	√ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√ None	

		Nam relat	e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	√	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√ 	None	
13	Other financial or non-financial interests	√	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			
	I certify that I have	answe	red every question and have not altered the wor	ding of any of the questions on this form.

Date:	10/31/2021
Your Name:	Charbel Mounayer
Manuscript Title:	Selective arterial temporary flow arrest with balloons during transvenous embolization for the treatment of brain arteriovenous malformations: a feasibility study with MRI-monitored adverse events
Manuscript Number (if known):	2021-018097.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Nam relat	e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above)	√	None Time frame: past 36 month None	Click the tab key to add additional rows.
2	Davallia		News	
3	Royaities or licenses		None	

1

		Name all entities with whom you have this	Specifications/Comments (a.g., if payments were
		relationship or indicate none (add rows as needed)	made to you or to your institution)
4	Consulting fees	√ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	√ None	
6	Payment for expert testimony	√ None	
7	Support for attending meetings and/or travel	√ None	
8	Patents planned, issued or pending	√ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	√ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√ None	

		Nam relat	e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	√	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√ 	None	
13	Other financial or non-financial interests	√	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			
	I certify that I have	answe	red every question and have not altered the wor	ding of any of the questions on this form.

Date:	10/31/2021
Your Name:	Jose Alberto Almeida Filho
Manuscript Title:	Selective arterial temporary flow arrest with balloons during transvenous embolization for the treatment of brain arteriovenous malformations: a feasibility study with MRI-monitored adverse events
Manuscript Number (if known):	2021-018097.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Nam relat	e all entities with whom you have this tionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work		
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	√	None Time frame: past 36 month None	Click the tab key to add additional rows.
3	Royalties or licenses	√	None	

1

		Name all entities with whom you have this	Specifications/Comments (a.g., if payments were
		relationship or indicate none (add rows as needed)	made to you or to your institution)
4	Consulting fees	√ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	√ None	
6	Payment for expert testimony	√ None	
7	Support for attending meetings and/or travel	√ None	
8	Patents planned, issued or pending	√ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	√ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√ None	

		Nam relat	e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√ 	None	
13	Other financial or non-financial interests		None	
Please place an "X" next to the following statement to indicate your agreement:				
	I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	10/31/2021
Your Name:	Suzana Saleme
Manuscript Title:	Selective arterial temporary flow arrest with balloons during transvenous embolization for the treatment of brain arteriovenous malformations: a feasibility study with MRI-monitored adverse events
Manuscript Number (if known):	2021-018097.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Nam relat	e all entities with whom you have this tionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work		
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	√	None Time frame: past 36 month None	Click the tab key to add additional rows.
3	Royalties or licenses	√	None	

1

		Name all entities with whom you have this	Specifications/Comments (a.g., if payments were
		relationship or indicate none (add rows as needed)	made to you or to your institution)
4	Consulting fees	√ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	√ None	
6	Payment for expert testimony	√ None	
7	Support for attending meetings and/or travel	√ None	
8	Patents planned, issued or pending	√ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	√ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√ None	

		Nam relat	e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√ 	None	
13	Other financial or non-financial interests		None	
Please place an "X" next to the following statement to indicate your agreement:				
	I certify that I have answered every question and have not altered the wording of any of the questions on this form.			